Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease

Kidney International

Volumn 87, Issue 1, 2015, Pages 116-127

  Eriguchi, Masahiro ^a   Tsuruya, Kazuhiko ^a   Haruyama, Naoki ^a   Yamada, Shunsuke ^a   Tanaka, Shigeru ^a   Suehiro, Takaichi ^a   Noguchi, Hideko ^a   Masutani, Kosuke ^a   Torisu, Kumiko ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin; Chronic kidney disease; Fibrosis; Renal ablation; Reninangiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; HYDRALAZINE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GLOMERULUS; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; KIDNEY DENERVATION; MACROPHAGE; MALE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RNA ANALYSIS; ADRENERGIC SYSTEM; ANIMAL; CARDIO-RENAL SYNDROME; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE MODEL; HEART DISEASES; INNERVATION; KIDNEY; PHYSIOLOGY; SYMPATHECTOMY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CARDIO-RENAL SYNDROME; DISEASE MODELS, ANIMAL; HEART DISEASES; KIDNEY; MALE; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84920263557     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.220     Document Type: Article

References (60)

1. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315.
2. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-67.
3. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
4. Bongartz LG, Cramer MJ, Doevendans PA et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 11-17.
5. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
6. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
7. Mahfoud F, Cremers B, Janker J et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-424.
8. Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946.
9. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
10. Brandt MC, Reda S, Mahfoud F et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60: 1956-1965.
11. Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250-1257.
12. Bhatt DL, Kandzari DE, O'Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
13. Jordan J, Mann JF, Luft FC. Research needs in The area of device-related treatments for hypertension. Kidney Int 2013; 84: 250-255.
14. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
15. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin-angiotensin system: from physiology to The pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
16. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-650.
17. Lu X, Roksnoer LC, Danser AH. The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice. Nephrol Dial Transplant 2013; 28: 2977-2982.
18. Levens NR, Peach MJ, Carey RM. Role of The intrarenal renin-angiotensin system in The control of renal function. Circ Res 1981; 48: 157-167.
19. Ellis B, Li XC, Miguel-Qin E et al. Evidence for a functional intracellular angiotensin system in The proximal tubule of The kidney. Am J Physiol Regul Integr Comp Physiol 2012; 302: R494-R509.
20. Sakai K, Agassandian K, Morimoto S et al. Local production of angiotensin II in The subfornical organ causes elevated drinking. J Clin Invest 2007; 117: 1088-1095.
21. Schinke M, Baltatu O, Bohm M et al. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci USA 1999; 96: 3975-3980.
22. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68: 905-921.
23. Sachetelli S, Liu Q, Zhang SL et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in The kidney. Kidney Int 2006; 69: 1016-1023.
24. Yamamoto T, Nakagawa T, Suzuki H et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1558-1565.
25. Kobori H, Ozawa Y, Satou R et al. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol 2007; 293: F938-F945.
26. Campese VM, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2002; 39: 519-524.
27. Domenighetti AA, Wang Q, Egger M et al. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 2005; 46: 426-432.
28. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493-498.
29. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007; 18: 208-214.
30. Matsusaka T, Niimura F, Pastan I et al. Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney Int 2013; 85: 1068-1077.
31. Nakano D, Kobori H, Burford JL et al. Multiphoton imaging of The glomerular permeability of angiotensinogen. J Am Soc Nephrol 2012; 23: 1847-1856.
32. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002; 61: 579-585.
33. Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 2001; 12: 431-439.
34. Palazzuoli A, Ronco C. Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially. Heart Fail Rev 2011; 16: 503-508.
35. Kopkan L, Cervenka L. Renal interactions of renin-angiotensin system, nitric oxide and superoxide anion: implications in The pathophysiology of salt-sensitivity and hypertension. Physiol Res 2009; 58(Suppl 2): S55-S67.
36. Bongartz LG, Braam B, Gaillard CA et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012; 303: F1253-F1263.
37. Shabeeh H, Seddon M, Brett S et al. Sympathetic activation increases NO release from eNOS but neither eNOS nor nNOS play an essential role in exercise hyperemia in The human forearm. Am J Physiol Heart Circ Physiol 2013; 304: H1225-H1230.
38. Kashiwagi M, Shinozaki M, Hirakata H et al. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000; 11: 616-624.
39. Ikeda H, Tsuruya K, Toyonaga J et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 2009; 75: 147-155.
40. Takemoto M, Egashira K, Usui M et al. Important role of tissue angiotensin-converting enzyme activity in The pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99: 278-287.
41. Sakuma I, Togashi H, Yoshioka M et al. NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in The central regulation of sympathetic tone? Circ Res 1992; 70: 607-611.
42. Rafiq K, Noma T, Fujisawa Y et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125: 1402-1413.
43. Rabkin R, Awwad I, Chen Y et al. Low-dose growth hormone is cardioprotective in uremia. J Am Soc Nephrol 2008; 19: 1774-1783.
44. Veelken R, Vogel EM, Hilgers K et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19: 1371-1378.
45. Nagasu H, Satoh M, Kuwabara A et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant 2010; 25: 2889-2898.
46. Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 2013; 24: 229-242.
47. Singh VP, Le B, Bhat VB et al. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 2007; 293: H939-H948.
48. Dostal DE, Booz GW, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol 2000; 95: 485-490.
49. Pohl M, Kaminski H, Castrop H et al. Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along The proximal nephron. J Biol Chem 2010; 285: 41935-41946.
50. Tian XL, Pinto YM, Costerousse O et al. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet 2004; 13: 1441-1450.
51. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 2013; 123: 2011-2023.
52. Yoo TH, Li JJ, Kim JJ et al. Activation of The renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-1027.
53. Kinugasa S, Tojo A, Sakai T et al. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int 2011; 80: 1328-1338.
54. Colindres RE, Spielman WS, Moss NG et al. Functional evidence for renorenal reflexes in The rat. Am J Physiol 1980; 239: F265-F270.
55. Kopp UC, Smith LA, DiBona GF. Renorenal reflexes: neural components of ipsilateral and contralateral renal responses. Am J Physiol 1985; 249: F507-F517.
56. Katwa LC, Campbell SE, Tyagi SC et al. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997; 29: 1375-1386.
57. Kitazono T, Padgett RC, Armstrong ML et al. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 1129-1134.
58. Gomez RA, Norling LL, Wilfong N et al. Leukocytes synthesize angiotensinogen. Hypertension 1993; 21: 470-475.
59. Levick SP, Murray DB, Janicki JS et al. Sympathetic nervous system modulation of inflammation and remodeling in The hypertensive heart. Hypertension 2010; 55: 270-276.
60. Miyazawa T, Zeng F, Wang S et al. Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression. Kidney Int 2013; 84: 1176-1188.